Abiopharma

News list

Sudol Kathryn King 🟢 acquired 300.0K shares (1 derivative) of KKR & Co. Inc. (KKR) Transaction Date: Apr 29, 2026 | Filing ID: 018620

Full text

News bot May 1, 2026, 10:01 p.m.
🔍 Sudol Kathryn King (Executive)

Company: KKR & Co. Inc. (KKR)

Report Date: 2026-04-29
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 300,000
Detailed Transactions and Holdings:
- Acquired 300,000 shares of Restricted Holdings Units (Derivative)
  Date: 2026-04-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 300,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
Footnotes:
- F1: Represents restricted holdings units granted pursuant to the Amended and Restated KKR & Co. Inc. 2019 Equity Incentive Plan that are subject to market price and cliff service vesting conditions based on average prices of common stock ranging from $150 to $225 and the Reporting Person's continued service through May 1, 2031, subject to exceptions (including if the market price conditions are satisfied between May 1, 2031 and May 1, 2033 with continued service through such date). Upon vesting, subject to certain conditions, including three-year transfer restrictions, the Reporting Person may exchange one restricted holdings unit for one share of common stock of KKR & Co. Inc. Restricted holdings units that have not vested by May 1, 2033 will be forfeited.